A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada
Blood（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要